Table 2.

VEGF-A, VEGF-B and PIGF levels in each group.

Groups	VEGF-A (pg/mL per mg tissue)	VEGF-B (pg/mL per mg tissue)	PIGF (pg/mL per mg tissue)
Control	439.6 ± 52.7	573.7 ± 102.3	30.4 ± 5.5
Subconjunctival bevacizumab	298.1 ± 31.9	601.7 ± 115.2	32.7 ± 7.3
Subconjunctival aflibercept	304.8 ± 49.2	345.7 ± 97.8	24.6 ± 5.4
Intrastromal bevacizumab	221.6 ± 57.5	560.5 ± 93.0	34.0 ± 5.2
Intrastromal aflibercept	239.0 ± 45.7	246.2 ± 54.5	19.3 ± 4.1
pa	<0.001***	<0.001***	0.003**

Bold values indicate statistical significance. Regarding VEGF-A level, in pairwise comparison with the control group, all intervention groups showed lower VEGF-A levels than the control group (p = 0.004 for subconjunctival bevacizumab vs. control, p = 0.010 for subconjuctival aflibercept vs control, p < 0.001 for intrastromal bevacizumab vs. control, and p < 0.001 for intrastromal aflibercept vs. control). Regarding VEGF-B level, in pairwise comparison with the control group, aflibercept groups showed lower VEGF-B levels than the control group (p = 1.000 for subconjunctival bevacizumab vs. control, p = 0.027 for subconjuctival aflibercept vs. control, p = 1.000 for intrastromal bevacizumab vs. control, and p = 0.002 for intrastromal aflibercept vs. control). Regarding PIGF level, in pairwise comparison with the control group, only the intrastromal aflibercept group showed lower PIGF levels than the control group (p = 1.000 for subconjunctival bevacizumab vs. control, p = 0.636 for subconjuctival aflibercept vs. control, p = 0.964 for intrastromal bevacizumab vs. control, and p = 0.031 for intrastromal aflibercept vs. control).

^aKruskal–Wallis test.